Sunil Badve's Publications

About Sunil Badve's Publications

Program Lead, Cardiometabolic Trials, Renal and Metabolic Program

  • EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS

    Date published:

  • The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial

    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Date published:

  • Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease

    Cochrane Database of Systematic Reviews Date published:

  • Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials

    Nephrology Dialysis Transplantation Date published:

  • Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients

    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Date published:

  • The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications

    BMC Nephrology Date published:

  • The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis

    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis Date published:

  • The rationale and design of the B eta-blocker to LO wer CA rdiovascular D ialysis E vents ( BLOCADE ) F easibility S tudy

    Nephrology Date published:

  • End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases

    American Journal of Nephrology Date published:

  • Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial

    Canadian Journal of Kidney Health and Disease Date published:

  • A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial

    American Journal of Kidney Diseases Date published:

  • Daily Home Hemodialysis: Balancing Cardiovascular Benefits With Infectious Harms

    American Journal of Kidney Diseases Date published:

  • MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS AND CLINICAL OUTCOMES IN ADULT KIDNEY TRANSPLANT RECIPIENTS

    Nephrology Date published:

  • DISPARITIES IN SURVIVAL OF DIALYSIS PATIENTS IN AUSTRALIA BASED UPON ETHNICITY AND COUNTRY OF BIRTH

    Nephrology Date published:

  • The Association between Body Mass Index and Mortality in Incident Dialysis Patients

    PLOS One Date published:

  • End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases

    Nephrology Dialysis Transplantation Date published: